Search Results

NanoViricides, Inc. reports that its clinical stage lead nanoviricide broad-spectrum antiviral drug candidate, NV-387, results in an ideal flat blood concentration profile for an extended time period upon oral administration in two different animal models.

NanoViricides, Inc. reports on the highly desirable blood concentration profile of its lead clinical stage broad-spectrum antiviral agent NV-387 upon intravenous administration in a non-human primate animal model.

After being known to have the largest stable in the Weight Management arena, Hi-Tech has cemented its position to become the leader in a new category for focus, concentration, and productivity products with the additional production capacity for Adderex® XR.

Alvotech announced a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S. Food and Drug Administration approved high-concentration interchangeable biosimilar to Humira.

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), the company’s interchangeable* biosimilar to Humira® (adalimumab), to treat multiple chronic inflammatory diseases.

The global over-the-counter (OTC) analgesics market size was reached USD 28.6 billion in 2022 and is projected to surpass around USD 40.93 billion by 2032, expanding at a CAGR of 3.7% from 2023 to 2032.

Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced that it has entered into a Co-Marketing Agreement with Illumina, Inc., a global leader in DNA sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally.